Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
作者信息
Premkumar Vikram, Comenzo Raymond, Lentzsch Suzanne
机构信息
Division of Hematology/Oncology, Columbia University Medical Center, New York, NY.
Division of Hematology/Oncology, Tufts Medical Center, Boston, MA.
出版信息
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):686-688. doi: 10.1016/j.clml.2019.07.003. Epub 2019 Jul 15.
Abstract
摘要
相似文献
1
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):686-688. doi: 10.1016/j.clml.2019.07.003. Epub 2019 Jul 15.
2
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.
Haematologica. 2018 Mar;103(3):e135-e137. doi: 10.3324/haematol.2017.183749. Epub 2018 Jan 19.
3
Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?
Int J Hematol. 2020 Aug;112(2):234-237. doi: 10.1007/s12185-020-02857-2. Epub 2020 Mar 23.
4
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18.
5
Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis.
Br J Haematol. 2021 May;193(3):674-677. doi: 10.1111/bjh.17380. Epub 2021 Mar 13.
6
Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.
Acta Haematol. 2020;143(5):500-503. doi: 10.1159/000504355. Epub 2020 Jan 2.
7
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Hematol Oncol. 2020 Aug;38(3):412-414. doi: 10.1002/hon.2736. Epub 2020 Apr 23.
8
A man with chest tightness and burning limbs.
BMJ. 2017 May 11;357:j1979. doi: 10.1136/bmj.j1979.
9
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
Amyloid. 2019 Sep;26(3):173-174. doi: 10.1080/13506129.2019.1615428. Epub 2019 Jun 22.
10
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.
Haematologica. 2024 Jul 1;109(7):2355-2358. doi: 10.3324/haematol.2024.285145.
引用本文的文献
1
Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation.
Curr Oncol. 2025 Jan 26;32(2):63. doi: 10.3390/curroncol32020063.
2
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.
Pathol Oncol Res. 2022 Feb 28;28:1610276. doi: 10.3389/pore.2022.1610276. eCollection 2022.
3
Current Updates on the Management of AL Amyloidosis.
J Hematol. 2021 Aug;10(4):147-161. doi: 10.14740/jh866. Epub 2021 Aug 4.
4
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.
Exp Hematol Oncol. 2021 Jul 20;10(1):43. doi: 10.1186/s40164-021-00236-z.
5
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w.
6
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.
Front Pharmacol. 2020 Jul 10;11:1024. doi: 10.3389/fphar.2020.01024. eCollection 2020.
7
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.
J Blood Med. 2019 Oct 23;10:373-380. doi: 10.2147/JBM.S183857. eCollection 2019.
本文引用的文献
1
Use of novel therapies in the treatment of light chain amyloidosis.
Blood Rev. 2019 Sep;37:100581. doi: 10.1016/j.blre.2019.05.005. Epub 2019 May 22.
2
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
3
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.
4
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.
Blood. 2005 Oct 15;106(8):2837-40. doi: 10.1182/blood-2005-04-1411. Epub 2005 Jun 23.
Zotero 插件